NMR Spectroscopy-Based Metabolic Profiling of Drug-Induced Changes In Vitro Can Discriminate between Pharmacological Classes

Drug-induced changes in mammalian cell line models have already been extensively profiled at the systemic mRNA level and subsequently used to suggest mechanisms of action for new substances, as well as to support drug repurposing, i.e., identifying new potential indications for drugs already licensed for other pharmacotherapy settings. The seminal work in this field, which includes a large database and computational algorithms for pattern matching, is known as the "Connectivity Map" (CMap). However, the potential of similar exercises at the metabolite level is still largely unexplored. Only recently, the first high-throughput metabolomic assay pilot study was published, which involved screening the metabolic response to a set of 56 kinase inhibitors in a 96-well format. Here, we report results from a separately developed metabolic profiling assay, which leverages (1)H NMR spectroscopy to the quantification of metabolic changes in the HCT116 colorectal cancer cell line, in response to each of 26 compounds. These agents are distributed across 12 different pharmacological classes covering a broad spectrum of bioactivity. Differential metabolic profiles, inferred from multivariate spectral analysis of 18 spectral bins, allowed clustering of the most-tested drugs, according to their respective pharmacological class. A more-advanced supervised analysis, involving one multivariate scattering matrix per pharmacological class and using only 3 spectral bins (3 metabolites), showed even more distinct pharmacology-related cluster formations. In conclusion, this type of relatively fast and inexpensive profiling seems to provide a promising alternative to that afforded by mRNA expression analysis, which is relatively slow and costly. As also indicated by the present pilot study, the resulting metabolic profiles do not seem to provide as information-rich signatures as those obtained using systemic mRNA profiling, but the methodology holds strong promise for significant refinement.

[1]  D G Robertson,et al.  Metabolomics in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[2]  L. Frydman,et al.  Two-dimensional RF pulses: a new approach to selectively exciting J-coupled spins in nuclear magnetic resonance. , 2013, The Journal of chemical physics.

[3]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[4]  Nigel W. Hardy,et al.  Proposed minimum reporting standards for chemical analysis , 2007, Metabolomics.

[5]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[6]  A. Fernie,et al.  Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.

[7]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[8]  S. Thomas,et al.  Use of SERMs for treatment in postmenopausal women , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  A. Zhang,et al.  NMR‐based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis , 2013, Magnetic resonance in chemistry : MRC.

[10]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[11]  D. Ekman,et al.  A direct cell quenching method for cell-culture based metabolomics , 2009, Metabolomics.

[12]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[13]  Yongzhi Yang,et al.  Metabolomics in the fields of oncology: a review of recent research , 2012, Molecular Biology Reports.

[14]  Claes R. Andersson,et al.  Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance , 2013, BMC Cancer.

[15]  Kanika Chawla,et al.  Oncometabolomics in cancer research , 2013, Expert review of proteomics.

[16]  H. Koltai,et al.  Specificity of DNA microarray hybridization: characterization, effectors and approaches for data correction , 2008, Nucleic acids research.

[17]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[18]  A. Tomassini,et al.  Effects of resveratrol on HepG2 cells as revealed by (1)H-NMR based metabolic profiling. , 2012, Biochimica et biophysica acta.

[19]  M. Tashiro,et al.  BASHD‐J‐resolved‐COSY: a new method for measuring proton‐proton spin coupling constants of multiplet signals , 2012, Magnetic resonance in chemistry : MRC.

[20]  N. Bouchemal,et al.  Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells , 2010, NMR in biomedicine.

[21]  Xi-jun Wang,et al.  Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. , 2011, Journal of separation science.

[22]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[23]  A. Isaksson,et al.  Phenotype-Based Screening of Mechanistically Annotated Compounds in Combination with Gene Expression and Pathway Analysis Identifies Candidate Drug Targets in a Human Squamous Carcinoma Cell Model , 2006, Journal of biomolecular screening.

[24]  Mårten Fryknäs,et al.  In Vitro Drug Sensitivity-Gene Expression Correlations Involve a Tissue of Origin Dependency , 2007, J. Chem. Inf. Model..

[25]  M. Tashiro,et al.  Selective COSY‐J‐resolved‐HMBC, a new method for improving sensitivity of cross peaks of methine proton signals attached to a methyl group , 2012, Magnetic resonance in chemistry : MRC.

[26]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[27]  Mårten Fryknäs,et al.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.

[28]  Mårten Fryknäs,et al.  Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[29]  G. Westman,et al.  Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. , 2011, Biochemical pharmacology.

[30]  W. N. Chen,et al.  Metabolic profiling of HepG2 cells incubated with S(−) and R(+) enantiomers of anti-coagulating drug warfarin , 2010, Metabolomics.

[31]  Giovanni Paternostro,et al.  Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library. , 2011, Nature communications.

[32]  R. Larsson,et al.  Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. , 2012, Experimental cell research.

[33]  H. Keun,et al.  Application of metabonomics in drug development. , 2007, Pharmacogenomics.

[34]  D. Kell,et al.  Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery☆ , 2014, Drug discovery today.

[35]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[36]  V. Gogvadze,et al.  Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments , 2014, Nature Communications.

[37]  L. Påhlman,et al.  Novel activity of acriflavine against colorectal cancer tumor cells , 2011, Cancer science.

[38]  Xi-jun Wang,et al.  Modern analytical techniques in metabolomics analysis. , 2012, The Analyst.

[39]  S. Linder,et al.  Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells. , 2013, Biochemical and biophysical research communications.

[40]  M. Čuperlović-Culf,et al.  Cell culture metabolomics: applications and future directions. , 2010, Drug discovery today.

[41]  Mark R. Viant,et al.  Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines , 2009, PloS one.